The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction.
Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites.
The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
Elevated triglycerides and atherosclerotic cardiovascular disease are significant predictors of major cardiovascular events and increased health care costs in statin-treated patients: a real-world analysis [abstract I15].
Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events
Eicosapentaenoic acid inhibits oxidation of very large density lipoproteins (VLDL) in a dose-dependent manner over time as compared to docosahexaenoic acid in vitro [abstract].
Eicosapentaenoic acid inhibits high density lipoprotein (HDL) oxidation in a synergistic manner in combination with atorvastatin in vitro [abstract].
Long-term statin persistence is poor among high-risk patients with baseline peripheral artery disease: a real-world administrative claims analysis of the Optum research database
Increased residual cardiovascular risk in US veterans and moderately-elevated baseline triglycerides and well-controlled LCL-C levels on statins
Eicosapentaenoic acid inhibits membrane lipid oxidation in a concentration-dependent manner at pharmacologic doses in vitro
Long-term renal function worsens in high cardiovascular risk patients with high triglycerides and well-controlled low-density lipoprotein cholesterol in a real-world analysis
Long-term statin persistence is poor among high-risk patients with baseline diabetes: a real-world administrative claims analysis
Association between triglycerides and residual cardiovascular (CVD) risk in patients with type 2 diabetes and established CVD: an analysis of the BARI2D trial
Eicosapentaenoic acid (EPA) inhibits human HDL oxidation in a concentration-dependent manner at a pharmacologic dose in vitro.
Increased cardiovascular risk in patients with diabetes, statin-controlled LDL cholesterol, and residual hypertriglyceridemia
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro.
Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of new heart failure diagnosis: A real-world analysis of high-risk statin-treated patients.
Risk of cardiovascular events in patients with hypertriglyceridemia: a review of real-world evidence